These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1081 related articles for article (PubMed ID: 30120962)

  • 81. Tau Proteins and Tauopathies in Alzheimer's Disease.
    Chong FP; Ng KY; Koh RY; Chye SM
    Cell Mol Neurobiol; 2018 Jul; 38(5):965-980. PubMed ID: 29299792
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Do astrocytes collaborate with neurons in spreading the "infectious" aβ and Tau drivers of Alzheimer's disease?
    Dal Prà I; Chiarini A; Gui L; Chakravarthy B; Pacchiana R; Gardenal E; Whitfield JF; Armato U
    Neuroscientist; 2015 Feb; 21(1):9-29. PubMed ID: 24740577
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Association of Cancer History with Alzheimer's Disease Dementia and Neuropathology.
    Yarchoan M; James BD; Shah RC; Arvanitakis Z; Wilson RS; Schneider J; Bennett DA; Arnold SE
    J Alzheimers Dis; 2017; 56(2):699-706. PubMed ID: 28035936
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Tau and Aβ imaging, CSF measures, and cognition in Alzheimer's disease.
    Brier MR; Gordon B; Friedrichsen K; McCarthy J; Stern A; Christensen J; Owen C; Aldea P; Su Y; Hassenstab J; Cairns NJ; Holtzman DM; Fagan AM; Morris JC; Benzinger TL; Ances BM
    Sci Transl Med; 2016 May; 8(338):338ra66. PubMed ID: 27169802
    [TBL] [Abstract][Full Text] [Related]  

  • 85. SLOH, a carbazole-based fluorophore, mitigates neuropathology and behavioral impairment in the triple-transgenic mouse model of Alzheimer's disease.
    Wu X; Kosaraju J; Zhou W; Tam KY
    Neuropharmacology; 2018 Mar; 131():351-363. PubMed ID: 29309769
    [TBL] [Abstract][Full Text] [Related]  

  • 86. [Expression of apolipoprotein E in Alzheimer's disease and its significance].
    He SR; Liu DG; Wang S; Xia YJ
    Zhonghua Bing Li Xue Za Zhi; 2005 Sep; 34(9):556-60. PubMed ID: 16468304
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Tau Positive Neurons Show Marked Mitochondrial Loss and Nuclear Degradation in Alzheimer's Disease.
    Wee M; Chegini F; Power JHT; Majd S
    Curr Alzheimer Res; 2018; 15(10):928-937. PubMed ID: 29895248
    [TBL] [Abstract][Full Text] [Related]  

  • 88. The toxicity of tau in Alzheimer disease: turnover, targets and potential therapeutics.
    Pritchard SM; Dolan PJ; Vitkus A; Johnson GV
    J Cell Mol Med; 2011 Aug; 15(8):1621-35. PubMed ID: 21348938
    [TBL] [Abstract][Full Text] [Related]  

  • 89. I716F AβPP mutation associates with the deposition of oligomeric pyroglutamate amyloid-β and α-synucleinopathy with Lewy bodies.
    Sieczkowski E; Milenkovic I; Venkataramani V; Giera R; Ströbel T; Höftberger R; Liberski PP; Auff E; Wirths O; Bayer TA; Kovacs GG
    J Alzheimers Dis; 2015; 44(1):103-14. PubMed ID: 25182745
    [TBL] [Abstract][Full Text] [Related]  

  • 90. The dorsal raphe nucleus shows phospho-tau neurofibrillary changes before the transentorhinal region in Alzheimer's disease. A precocious onset?
    Grinberg LT; Rüb U; Ferretti RE; Nitrini R; Farfel JM; Polichiso L; Gierga K; Jacob-Filho W; Heinsen H;
    Neuropathol Appl Neurobiol; 2009 Aug; 35(4):406-16. PubMed ID: 19508444
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Neurofibrillary tangle formation by introducing wild-type human tau into APP transgenic mice.
    Umeda T; Maekawa S; Kimura T; Takashima A; Tomiyama T; Mori H
    Acta Neuropathol; 2014 May; 127(5):685-98. PubMed ID: 24531886
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Disordered APP metabolism and neurovasculature in trauma and aging: Combined risks for chronic neurodegenerative disorders.
    Ikonomovic MD; Mi Z; Abrahamson EE
    Ageing Res Rev; 2017 Mar; 34():51-63. PubMed ID: 27829172
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Dendritic Tau in Alzheimer's Disease.
    Ittner A; Ittner LM
    Neuron; 2018 Jul; 99(1):13-27. PubMed ID: 30001506
    [TBL] [Abstract][Full Text] [Related]  

  • 94. The Implications of Autophagy in Alzheimer's Disease.
    Hamano T; Hayashi K; Shirafuji N; Nakamoto Y
    Curr Alzheimer Res; 2018; 15(14):1283-1296. PubMed ID: 30289076
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Synaptic Loss, ER Stress and Neuro-Inflammation Emerge Late in the Lateral Temporal Cortex and Associate with Progressive Tau Pathology in Alzheimer's Disease.
    Buchanan H; Mackay M; Palmer K; Tothová K; Katsur M; Platt B; Koss DJ
    Mol Neurobiol; 2020 Aug; 57(8):3258-3272. PubMed ID: 32514860
    [TBL] [Abstract][Full Text] [Related]  

  • 96. [Present and future of the tau dementia therapy].
    Takashima A
    Rinsho Shinkeigaku; 2013; 53(11):1040-2. PubMed ID: 24291873
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Delta-secretase cleavage of Tau mediates its pathology and propagation in Alzheimer's disease.
    Kang SS; Ahn EH; Ye K
    Exp Mol Med; 2020 Aug; 52(8):1275-1287. PubMed ID: 32859953
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Comparison of Amyloid β and Tau Spread Models in Alzheimer's Disease.
    Kim HR; Lee P; Seo SW; Roh JH; Oh M; Oh JS; Oh SJ; Kim JS; Jeong Y
    Cereb Cortex; 2019 Sep; 29(10):4291-4302. PubMed ID: 30566579
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Pathways by which Abeta facilitates tau pathology.
    Blurton-Jones M; Laferla FM
    Curr Alzheimer Res; 2006 Dec; 3(5):437-48. PubMed ID: 17168643
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Molecular Mechanism of Autophagy: Its Role in the Therapy of Alzheimer's Disease.
    Zhao Y; Zhang Y; Zhang J; Zhang X; Yang G
    Curr Neuropharmacol; 2020; 18(8):720-739. PubMed ID: 31934838
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 55.